Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension

PURPOSE: Studies comparing the two different formulations of bimatoprost, 0.03% and 0.01%, have shown similar efficacy, but a better adverse effect profile for bimatoprost 0.01% in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). This study assesses the efficacy and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Kai Man, Cho, Ryan, Chan, Toby Yiu Bong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346412/
https://www.ncbi.nlm.nih.gov/pubmed/35936971
http://dx.doi.org/10.2147/OPTH.S368214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346412/
https://www.ncbi.nlm.nih.gov/pubmed/35936971
http://dx.doi.org/10.2147/OPTH.S368214

Ejemplares similares